drugset / Trial / NCT01229410

Pharmacokinetics of the Brimonidine Tartrate Posterior Segment Delivery System in Patients Undergoing Pars Plana Vitrectomy

NCT01229410

Phase 1 Completed 24 enrolled Allergan
RandomizedParallel-groupDouble-blindBasic science

Summary

This study will evaluate the pharmacokinetics of brimonidine following a single intravitreal administration of the 200 ug or 400 ug Brimonidine Tartrate Posterior Segment Drug Delivery System in patients 2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy.

Timeline

Start
2010-12
Primary completion
2011-05
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Brimonidine Small molecule 200 ug Intravitreal
Subject Brimonidine Small molecule 400 ug Intravitreal

Indications

No indication recorded.